Dual Approach to Disease: Eli Lilly’s Zepbound-Taltz Combination Demonstrates Breakthrough Results in Psoriasis Treatment

Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz for treating patients with both…

Continue Reading Dual Approach to Disease: Eli Lilly’s Zepbound-Taltz Combination Demonstrates Breakthrough Results in Psoriasis Treatment

Dual Targeting Psoriatic Arthritis and Obesity: Taltz–Zepbound Combo Sets New Benchmark in TOGETHER-PsA Trial

A first-of-its-kind Phase 3b study has shown that combining Eli Lilly’s Taltz (ixekizumab) with Zepbound (tirzepatide) delivers superior benefits for adults living with both active psoriatic arthritis (PsA) and obesity…

Continue Reading Dual Targeting Psoriatic Arthritis and Obesity: Taltz–Zepbound Combo Sets New Benchmark in TOGETHER-PsA Trial
Phase 2 Obesity Clinical Trial from Palatin Set to Begin
source: shutterstock.com

Phase 2 Obesity Clinical Trial from Palatin Set to Begin

According to a story from drugs.com, the biopharmaceutical company Palatin Technologies, Inc., which is specializing in the development of therapies that interact with the melanocortin receptor system, recently announced the…

Continue Reading Phase 2 Obesity Clinical Trial from Palatin Set to Begin

Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)
Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity
source: pixabay.com

Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity

According to a press release published on Globe Newswire, the biopharmaceutical company Saniona has announced recently that its investigational therapy Tesomet has recently earned Orphan Drug designation from the US…

Continue Reading Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity
Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome
source: pixabay.com

Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome

In a recent press release, biopharmaceutical company Rhythm Pharmaceuticals (“Rhythm”) announced positive data from a Phase 3 clinical trial. During the trial, Rhythm evaluated setmelanotide for patients with Bardet-Biedl syndrome…

Continue Reading Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome

Study: The Relationship Between Obesity, Lung Diseases, and Pulmonary Hypertension in Transplant Patients

The United States is coping with an obesity epidemic. It is therefore critical to understand the distribution of body fat and its effect on treatment. A recent article in Healio…

Continue Reading Study: The Relationship Between Obesity, Lung Diseases, and Pulmonary Hypertension in Transplant Patients